Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (1-10 of 578) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Chairperson's introduction: Surgical skills, especially in the upper abdomen, remain pivotal in the treatment of advanced ovarian cancerIgnace Vergote
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2004
Adjuvant therapy for early staged (epithelial) cancerIgnace Vergote
Expert Opinion on Investigational Drugs|March 25, 2014
Novel therapies, including enzastaurin, in the treatment of ovarian cancerIgnace Vergote
Human Pathology|April 4, 2003
Bifunctional pathway of uterine carcinosarcomasFrédéric Amant, Ignace Vergote
Gynecologic Oncology|September 19, 2006
Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancerIgnace Vergote, Frederic Amant
American Journal of Obstetrics and Gynecology|July 13, 2002
PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomasFrederic Amant, Ignace Vergote
Gynecologic Oncology|September 9, 2010
What is the role of neoadjuvant chemotherapy in advanced endometrial cancer?Frédéric Amant, Ignace Vergote
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 12, 2023
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first, do no harmLuis Chiva, Ignace Vergote
Cancer Treatment Reviews|May 24, 2005
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancerDavid Dodwell, Ignace Vergote
Gynecologic Oncology|March 30, 2004
Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcomaFrederic Amant, Ignace Vergote
Pageof 58

Showing results (1-10 of 578) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Chairperson's introduction: Surgical skills, especially in the upper abdomen, remain pivotal in the treatment of advanced ovarian cancerIgnace Vergote
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 4, 2004
Adjuvant therapy for early staged (epithelial) cancerIgnace Vergote
Expert Opinion on Investigational Drugs|March 25, 2014
Novel therapies, including enzastaurin, in the treatment of ovarian cancerIgnace Vergote
Human Pathology|April 4, 2003
Bifunctional pathway of uterine carcinosarcomasFrédéric Amant, Ignace Vergote
Gynecologic Oncology|September 19, 2006
Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancerIgnace Vergote, Frederic Amant
American Journal of Obstetrics and Gynecology|July 13, 2002
PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomasFrederic Amant, Ignace Vergote
Gynecologic Oncology|September 9, 2010
What is the role of neoadjuvant chemotherapy in advanced endometrial cancer?Frédéric Amant, Ignace Vergote
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 12, 2023
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first, do no harmLuis Chiva, Ignace Vergote
Cancer Treatment Reviews|May 24, 2005
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancerDavid Dodwell, Ignace Vergote
Gynecologic Oncology|March 30, 2004
Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcomaFrederic Amant, Ignace Vergote
Pageof 58